Corona Remedies Ltd Upgraded to Buy by MarketsMOJO on Strong Fundamentals and Technicals
NiveshIQ
NSE: CORONA · Healthcare
CORONA Remedies Ltd.
₹1,993.50▼ ₹47.60 (-2.33%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on CORONA. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About CORONA Remedies Ltd.
Corona Remedies Limited is a mid‑cap pharmaceutical formulation company headquartered in Ahmedabad, India, with a diversified portfolio spanning women’s healthcare, cardio‑diabeto, pain management, urology, thyroid, respiratory, nutraceuticals, and gastroenterology. In FY23, the company generated ₹1,479 crore in revenue and ₹199 crore in net income, reflecting a 12% YoY revenue growth and a 15% increase in operating margin. Recent analyst coverage has been mixed; MarketsMojo upgraded the stock to Buy citing strong fundamentals but also noted technical weakness leading to a Hold rating, while Value Research highlighted attractive valuation multiples. The firm has been added to the S&P Global BMI Index, enhancing its visibility among institutional investors. Competitive positioning is bolste
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹1,014 Cr +14.70% | ₹1,196 Cr +17.90% | ₹1,403 Cr +17.40% |
| EBITDA Margin | 15.61% | 20.39% | 20.91% |
| Net Profit | ₹90.50 Cr +6.60% | ₹149.43 Cr +65.10% | ₹185.12 Cr +23.90% |
| EPS | ₹14.80 | ₹24.43 | ₹30.27 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
Corona Remedies Ltd Downgraded to Hold Amid Technical Weakness Despite Strong Fundamentals
Corona Remedies Ltd Downgraded to Hold Amid Technical Weakness Despite Strong Fundamentals
🔒
+ 3 more stories about CORONA Remedies Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q2FY27 results: revenue ₹441 Cr, PAT ₹60 Cr, EPS ₹9.86, EBITDA margin 21.7%. Growth context: revenue YoY +22.2%, PAT YoY +15.3%, revenue QoQ +4.4%, PAT QoQ +0.3%.
Recent corporate activity highlights product launches, approvals, and therapy-mix improvement and new capacity addition ...
FY26 (last completed FY): revenue ₹1, 403 Cr, PAT ₹185 Cr, EBITDA margin 20.9%, EPS ₹30.27. Year-on-year: revenue YoY +1...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for CORONA
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track CORONA alongside your other holdings
Unlock full CORONA research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for CORONA Remedies Ltd.?
NiveshIQ detects active intelligence signals for CORONA Remedies Ltd. (CORONA) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for CORONA Remedies Ltd.?
CORONA Remedies Ltd. operates in the Healthcare sector. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.